AUSTIN, Texas–(BUSINESS WIRE)–Babson Diagnostics (Babson), a transformative diagnostic blood testing company, announced today it has launched its first COVID-19 serology test to detect IgG antibodies to SARS-CoV-2 in the bloodstream through a select network of retail and clinical partners in Austin, Texas. Clinical performance evaluation for Babson’s IgG assay resulted in 93.2 percent sensitivity and 100.0 percent specificity.

Babson is developing a pipeline of fully automated COVID-19 serology assays, including qualitative and quantitative measurement of the immune response across a number of sample types. Babson’s tests are high-throughput heterogeneous immunoassays analyzed at the company’s CLIA-certified, CAP-accredited, high-complexity clinical laboratory in Austin.

“We’re encouraged by the early success and performance of our initial IgG assay,” said Eric Olson, Babson’s founder and CEO. “Serology testing will be a critical measure for understanding COVID-19 and enabling frontline workers to continue to serve the community. We project that our network of partners will enable us to scale our testing service to tens of thousands of tests per week, helping Austin’s health care community gain a new understanding of the virus’s impact on our city and surrounding areas.”

Babson plans to deploy thousands of tests to essential retail and clinical partners such as grocery stores and pharmacies as well as various health care and social services organizations. The first wave of tests will be delivered pro bono to participating organizations for frontline employees, providing trusted, high-quality serology testing in Austin and its surrounding areas to rapidly advance the understanding of COVID-19 and support Texas’ reopening strategy.

About Babson Diagnostics

Babson Diagnostics aims to bring diagnostic blood testing to the retail pharmacy counter, making it easier, faster, and more pleasant for customers to routinely monitor and improve their health. Babson’s proprietary technological ecosystem is designed to deliver accurate diagnostic results with a more human experience. Based in Austin, Texas, its vision for diagnostic blood testing—built on accuracy, convenience, and accessibility—combines transformative diagnostic technology with a customer-first, retail-centric business model that aims to improve customer health and experience. Prior to commercialization, Babson is working with retail pharmacies to validate its technology by conducting clinical studies intended for peer-reviewed publication. For more information, please visit


For media inquiries only:

Emma Chase

(c) 512-917-4319

For general inquiries:


Subscribe to Our Newsletter (coming soon)

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.